INVO Fertility Q2 Revenue Up 17%, Clinic Platform Turns Profitable
IVF has more than doubled off its 52-week low of $0.9.
Summary
INVO Fertility reported Q2 2026 revenue of $2.18 million, up 17% year-over-year, driven by the first full-quarter contribution from Family Beginnings and organic growth at existing clinics. Clinic-Level Adjusted EBITDA reached $333,000, up from $164,000 in Q1 2026, marking the platform's profitability before corporate expenses. Net income swung to $0.9 million from a $3.6 million loss a year ago, boosted by a $2.5 million gain on the Birmingham acquisition remeasurement. Cash stood at $3.7 million at quarter-end. The company remains highly leveraged to its equity line with Alumni Capital, and the clinic-level profitability is a key step toward offsetting corporate overhead.
Updates
· Benzinga — Shares surged 53% to $1.49 after the surprise profit.
At the time of this announcement, IVF was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.90 to $84.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.